302 related articles for article (PubMed ID: 37830586)
1. PAK1 and Therapy Resistance in Melanoma.
Kichina JV; Maslov A; Kandel ES
Cells; 2023 Sep; 12(19):. PubMed ID: 37830586
[TBL] [Abstract][Full Text] [Related]
2. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
Ong CC; Jubb AM; Jakubiak D; Zhou W; Rudolph J; Haverty PM; Kowanetz M; Yan Y; Tremayne J; Lisle R; Harris AL; Friedman LS; Belvin M; Middleton MR; Blackwood EM; Koeppen H; Hoeflich KP
J Natl Cancer Inst; 2013 May; 105(9):606-7. PubMed ID: 23535073
[TBL] [Abstract][Full Text] [Related]
3. P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.
Babagana M; Johnson S; Slabodkin H; Bshara W; Morrison C; Kandel ES
Mol Carcinog; 2017 May; 56(5):1515-1525. PubMed ID: 28052407
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.
Eswaran J; Li DQ; Shah A; Kumar R
Clin Cancer Res; 2012 Jul; 18(14):3743-9. PubMed ID: 22595609
[TBL] [Abstract][Full Text] [Related]
5. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
[TBL] [Abstract][Full Text] [Related]
6. Increased p21-activated kinase-1 expression is associated with invasive potential in uveal melanoma.
Pavey S; Zuidervaart W; van Nieuwpoort F; Packer L; Jager M; Gruis N; Hayward N
Melanoma Res; 2006 Aug; 16(4):285-96. PubMed ID: 16845324
[TBL] [Abstract][Full Text] [Related]
7. Taming the wild-types: targeting PAK1 in melanomas that lack BRAF mutations.
Smalley KS; Weber JS
J Natl Cancer Inst; 2013 May; 105(9):591-2. PubMed ID: 23535072
[No Abstract] [Full Text] [Related]
8. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
9. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
[TBL] [Abstract][Full Text] [Related]
10. JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component.
Liu X; Si W; Liu X; He L; Ren J; Yang Z; Yang J; Li W; Liu S; Pei F; Yang X; Sun L
Mol Cancer; 2017 Nov; 16(1):175. PubMed ID: 29187213
[TBL] [Abstract][Full Text] [Related]
11. Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Jung ID; Lee J; Lee KB; Park CG; Kim YK; Seo DW; Park D; Lee HW; Han JW; Lee HY
Eur J Biochem; 2004 Apr; 271(8):1557-65. PubMed ID: 15066181
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.
Ong CC; Gierke S; Pitt C; Sagolla M; Cheng CK; Zhou W; Jubb AM; Strickland L; Schmidt M; Duron SG; Campbell DA; Zheng W; Dehdashti S; Shen M; Yang N; Behnke ML; Huang W; McKew JC; Chernoff J; Forrest WF; Haverty PM; Chin SF; Rakha EA; Green AR; Ellis IO; Caldas C; O'Brien T; Friedman LS; Koeppen H; Rudolph J; Hoeflich KP
Breast Cancer Res; 2015 Apr; 17(1):59. PubMed ID: 25902869
[TBL] [Abstract][Full Text] [Related]
13. ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration.
Yuan L; Santi M; Rushing EJ; Cornelison R; MacDonald TJ
Clin Exp Metastasis; 2010 Oct; 27(7):481-91. PubMed ID: 20526801
[TBL] [Abstract][Full Text] [Related]
14. P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer.
Yao D; Li C; Rajoka MSR; He Z; Huang J; Wang J; Zhang J
Theranostics; 2020; 10(21):9741-9766. PubMed ID: 32863957
[TBL] [Abstract][Full Text] [Related]
15. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
Wu DW; Wu TC; Chen CY; Lee H
Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
[TBL] [Abstract][Full Text] [Related]
16. Targeting Phosphorylation of p21-activated Kinase 1 at Thr423 Induces Cell Cycle Arrest and Apoptosis in Cutaneous T-cell Lymphoma Cells.
Wang Y; Li W; Zhang Q; Gu X; He X; Men Y; Zhang C
Acta Derm Venereol; 2019 Oct; 99(11):1022-1028. PubMed ID: 31304555
[TBL] [Abstract][Full Text] [Related]
17. RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
Foth M; Parkman G; Battistone B; McMahon M
Pigment Cell Melanoma Res; 2020 Sep; 33(5):719-730. PubMed ID: 32406574
[TBL] [Abstract][Full Text] [Related]
18. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
19. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
[TBL] [Abstract][Full Text] [Related]
20. The serum/PDGF-dependent "melanogenic" role of the minute level of the oncogenic kinase PAK1 in melanoma cells proven by the highly sensitive kinase assay.
Be Tu PT; Nguyen BC; Tawata S; Yun CY; Kim EG; Maruta H
Drug Discov Ther; 2017 Jan; 10(6):314-322. PubMed ID: 27746419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
